|
|
Post by tw12 on Sept 5, 2017 8:46:00 GMT -5
There is an enlightening, new conversation barely begun on the planet. It is between, on the one hand, the half billion people who have diabetes and, on the other hand, Mike Castanga and his Giant Killers. I’ll bet none of us, not even Mike, has any idea of just how powerful this conversation will become. But I’ll bet that Al Mann did.
Mike’s Giant Killers are of course not only his hired team, they are you and I, folks keen about the life-changing potential of Afrezza. Every day, as a 69-year old ride-sharing driver in Massachusetts (who had two sisters die from diabetic complications), I introduce Afrezza -- “the miracle, monomer insulin; the inspired insulin” -- to strangers. Their reaction is almost always engaged and positive, excited to take action, to spread the word.
Inevitably, over the next few years, this conversation will engage Earth’s half-billion diabetics (not to mention four hundred million so-called pre-diabetics), for the evidence is now overwhelming that Afrezza can help them live a much better life. Again, Al Mann knew this.
And, I suspect, much to Big Pharma’s chagrin, this is a conversation they cannot stop or even diminish, for -- thanks to Mike’s strategy of talking with diabetics in a way that honors their courage, that recognizes their everyday challenge to utterly customize their self-care -- Mike and his Giant Killers are helping to create a new paradigm of not just care but of communication. Happily this conversation is out of Big Pharma’s control, as thousands of people are hearing the hard truth about Afrezza’s efficacy everyday. Perhaps, indeed, this is a revolution that will force Big Pharma to come to new terms with their too-often immoral and greedy way of doing business.
Meanwhile, Mike and us giant killers never will sell out mankind.
|
|
|
|
Post by kbrion77 on Sept 5, 2017 8:57:35 GMT -5
There is an enlightening, new conversation barely begun on the planet. It is between, on the one hand, the half billion people who have diabetes and, on the other hand, Mike Castanga and his Giant Killers. I’ll bet none of us, not even Mike, has any idea of just how powerful this conversation will become. But I’ll bet that Al Mann did. Mike’s Giant Killers are of course not only his hired team, they are you and I, folks keen about the life-changing potential of Afrezza. Every day, as a 69-year old ride-sharing driver in Massachusetts (who had two sisters die from diabetic complications), I introduce Afrezza - “the miracle, monomer insulin; the inspired insulin” -- to strangers. Their reaction is almost always engaged and positive, excited to take action, to spread the word. Inevitably, over the next few years, this conversation will engage Earth’s half-billion diabetics (not to mention four hundred million so-called pre-diabetics), for the evidence is now overwhelming that Afrezza can help them live a much better life. Again, Al Mann knew this. And, I suspect, much to Big Pharma’s chagrin, this is a conversation they cannot stop or even diminish, for -- thanks to Mike’s strategy of talking with diabetics in a way that honors their courage, that recognizes their everyday challenge to utterly customize their self-care -- Mike and his Giant Killers are helping to create a new paradigm of not just care but of communication. Happily this conversation is out of Big Pharma’s control, as thousands of people are hearing the hard truth about Afrezza’s efficacy everyday. Perhaps, indeed, this is a revolution that will force Big Pharma to come to new terms with their too-often immoral and greedy way of doing business. Meanwhile, Mike and us giant killers never will sell out mankind.Mike and the board have shareholders to answer to. People need to remember that this is a publicly traded company not private. If Lilly were to offer $25 per share for a buyout then it's done and it is sold and you move on. |
|
|
|
Post by peppy on Sept 5, 2017 9:01:02 GMT -5
There is an enlightening, new conversation barely begun on the planet. It is between, on the one hand, the half billion people who have diabetes and, on the other hand, Mike Castanga and his Giant Killers. I’ll bet none of us, not even Mike, has any idea of just how powerful this conversation will become. But I’ll bet that Al Mann did. Mike’s Giant Killers are of course not only his hired team, they are you and I, folks keen about the life-changing potential of Afrezza. Every day, as a 69-year old ride-sharing driver in Massachusetts (who had two sisters die from diabetic complications), I introduce Afrezza - “the miracle, monomer insulin; the inspired insulin” -- to strangers. Their reaction is almost always engaged and positive, excited to take action, to spread the word. Inevitably, over the next few years, this conversation will engage Earth’s half-billion diabetics (not to mention four hundred million so-called pre-diabetics), for the evidence is now overwhelming that Afrezza can help them live a much better life. Again, Al Mann knew this. And, I suspect, much to Big Pharma’s chagrin, this is a conversation they cannot stop or even diminish, for -- thanks to Mike’s strategy of talking with diabetics in a way that honors their courage, that recognizes their everyday challenge to utterly customize their self-care -- Mike and his Giant Killers are helping to create a new paradigm of not just care but of communication. Happily this conversation is out of Big Pharma’s control, as thousands of people are hearing the hard truth about Afrezza’s efficacy everyday. Perhaps, indeed, this is a revolution that will force Big Pharma to come to new terms with their too-often immoral and greedy way of doing business. Meanwhile, Mike and us giant killers never will sell out mankind. There seems to be multiple control systems. (practicing) Medicine is general is based on a triple check system. /photo/1?ref_src=twsrc%5Etfw&ref_url=http%3A%2F%2Fmnkd.proboards.com%2Fthread%2F6532%2Fafrezza-on-twitter-ii%3Fpage%3D87
|
|
|
|
Post by akemp3000 on Sept 5, 2017 9:25:35 GMT -5
Love the title of this thread. Mike Castagna, thanks to Al Mann, is going to change the world of diabetes treatment forever. With regard to the idea that a $25 buyout offer means this is over and done just isn't true. It would merely represent a low ball first offer that starts the clock for epic strategies and probably a bidding war!!
|
|
|
|
Post by mango on Sept 5, 2017 9:47:49 GMT -5
There is an enlightening, new conversation barely begun on the planet. It is between, on the one hand, the half billion people who have diabetes and, on the other hand, Mike Castanga and his Giant Killers. I’ll bet none of us, not even Mike, has any idea of just how powerful this conversation will become. But I’ll bet that Al Mann did. Mike’s Giant Killers are of course not only his hired team, they are you and I, folks keen about the life-changing potential of Afrezza. Every day, as a 69-year old ride-sharing driver in Massachusetts (who had two sisters die from diabetic complications), I introduce Afrezza - “the miracle, monomer insulin; the inspired insulin” -- to strangers. Their reaction is almost always engaged and positive, excited to take action, to spread the word. Inevitably, over the next few years, this conversation will engage Earth’s half-billion diabetics (not to mention four hundred million so-called pre-diabetics), for the evidence is now overwhelming that Afrezza can help them live a much better life. Again, Al Mann knew this. And, I suspect, much to Big Pharma’s chagrin, this is a conversation they cannot stop or even diminish, for -- thanks to Mike’s strategy of talking with diabetics in a way that honors their courage, that recognizes their everyday challenge to utterly customize their self-care -- Mike and his Giant Killers are helping to create a new paradigm of not just care but of communication. Happily this conversation is out of Big Pharma’s control, as thousands of people are hearing the hard truth about Afrezza’s efficacy everyday. Perhaps, indeed, this is a revolution that will force Big Pharma to come to new terms with their too-often immoral and greedy way of doing business. Meanwhile, Mike and us giant killers never will sell out mankind.Mike and the board have shareholders to answer to. People need to remember that this is a publicly traded company not private. If Lilly were to offer $25 per share for a buyout then it's done and it is sold and you move on. MannKind is invaluable to the future health of all humankind. And $25 is a joke. |
|
|
|
Post by casualinvestor on Sept 5, 2017 10:01:01 GMT -5
Realistically, I'd think that every single institution holder other than ALFRED E. MANN LIVING TRUST would sell for $10/share, as that's a 500% upside on current PPS.
I'd like to see MNKD continue to grow with Afrezza and develop new drugs lines. But what defense is there against a company that is willing to drop $1-2 billion on taking this over? Just curious...
|
|
|
|
Post by slugworth008 on Sept 5, 2017 10:05:32 GMT -5
Love the title of this thread. Mike Castagna, thanks to Al Mann, is going to change the world of diabetes treatment forever. With regard to the idea that a $25 buyout offer means this is over and done just isn't true. It would merely represent a low ball first offer that starts the clock for epic strategies and probably a bidding war!! If you can't beat'm buy'm. I've always believed that MNKD will be bought out once BP realizes they can't kill Afrezza - IMO And I also believe one hell of a bidding war will take place. JMHO |
|
|
|
Post by madog365 on Sept 5, 2017 10:51:18 GMT -5
Realistically, I'd think that every single institution holder other than ALFRED E. MANN LIVING TRUST would sell for $10/share, as that's a 500% upside on current PPS. I'd like to see MNKD continue to grow with Afrezza and develop new drugs lines. But what defense is there against a company that is willing to drop $1-2 billion on taking this over? Just curious... Mannkind is not a threat to big pharma in its current state ONLY because they have no cash to market the hell out of this amazing drug. If one of the big diabetes players wanted to buy Afrezza, and it became public, it would scare the hell out of the competition because deep pockets with ability to to invest in afrezza has potential to destroy all of the competitive products and diabetes franchises keeping some of these companies afloat. Do you really think they would allow that to happen without a bidding war? $1-$2 billion is peanuts to them in the grand scheme of diabetes franchises. Lantus’ total lifetime sales are expected to amount to more than $80 billion. And bringing a new diabetes drug to market is over $3b alone... and that's sunk cost without even knowing whether it will get approved. |
|
|
|
Post by mnholdem on Sept 5, 2017 11:06:29 GMT -5
You know, sooner or later, some big pharmaceutical companies will begin to realize the credibility of MannKind's Technosphere drug delivery system and the benefits pulmonary delivery offers, like minimizing common side-effects inherent with delivering drugs with pills and injections, and starting reaching into their deep pockets.
The trepostinil (PAH) development - which has been moved up the pipeline - will be important for expanding awareness that MannKind has much MORE to offer than a fantastic prandial insulin.
 |
|
|
|
Post by peppy on Sept 5, 2017 11:20:54 GMT -5
You know, sooner or later, some big pharmaceutical companies will begin to realize the credibility of MannKind's Technosphere drug delivery system and the benefits pulmonary delivery offers, like minimizing common side-effects inherent with delivering drugs with pills and injections, and starting reaching into their deep pockets.
The trepostinil (PAH) development - which has been moved up the pipeline - will be important for expanding awareness that MannKind has much MORE to offer than a fantastic prandial insulin.
I see the humor that trepostinil is the one the fda is most excited about. side note, when I did additional reading on Pulmonary hypertension it is/has been treated with Sildenafil = Viagra. oh the humor.
|
|
|
|
Post by mike0475 on Sept 5, 2017 11:33:16 GMT -5
I want to know who was behind the scenes restructuring management
Was Matt part of the overall plan or part of the plan to be removed by other to get this company across the finish line?
Connections between board and Mann trust to initiate the exec overhaul?
|
|
|
|
Post by lakon on Sept 5, 2017 11:34:57 GMT -5
My hope is that by the time BP awakes from their slumber, the MNKD train will have already left the station with the Afrezza engine driving the Technosphere cars. If all goes well, perhaps, MNKD will let BP ride in the caboose...
|
|
|
|
Post by lakon on Sept 5, 2017 11:37:01 GMT -5
I want to know who was behind the scenes restructuring management Was Matt part of the overall plan or part of the plan to be removed by other to get this company across the finish line? Connections between board and Mann trust to initiate the exec overhaul? This is what Kent Kresa did at Northrop... |
|
|
|
Post by mike0475 on Sept 5, 2017 11:40:21 GMT -5
Thought Kresa would be part of pitching change
Didn't he help ford avoid the cash for clunkers bk era?
|
|
|
|
Post by akemp3000 on Sept 5, 2017 11:54:17 GMT -5
I want to know who was behind the scenes restructuring management Was Matt part of the overall plan or part of the plan to be removed by other to get this company across the finish line? Connections between board and Mann trust to initiate the exec overhaul? Kent Kresa was most likely driving the background decisions. Matt's experience as CFO was needed to get through the difficult SNY transition. Once completed, Mike moved into the CEO slot with the necessary experience related to marketing, sales and growth. Mike has developed an extensive pipeline of opportunistic partnerships and significantly expanded the sales force with non-paid celebrity and other relationships. He's good! |
|
